This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.
RSA 318-B:15 · Persons and Corporations Exempted
318-B:15 Persons and Corporations Exempted. – The provisions of this chapter restricting the possession and having control of controlled drugs shall not apply to:
Copy linkCommon carriers or to warehousemen while engaged in lawfully transporting or storing such drugs, or to an employee of the same acting within the scope of his employment; or to public officers or their employees in the performance of their official duties requiring possession or control of controlled drugs; or to temporary incidental possession by employees or agents or persons lawfully entitled to possession, or by persons whose possession is for the purpose of aiding public officers in performing their official duties.
Copy linkPersons possessing prescription drugs dispensed to them pursuant to a lawful prescription or who are acting as an authorized agent for a person holding a lawful prescription. For purposes of this section, an authorized agent shall mean any person, including but not limited to a family member or caregiver, who has the intent to deliver the prescription drug to the person to whom the prescription drugs are lawfully prescribed. This exemption does not extend to persons possessing drugs with an intent to sell.
Copy linkLaw enforcement officers engaged in the collection, storage, and disposal of controlled drugs in conjunction with a pharmaceutical drug take-back program established under RSA 318-E.
Copy link(a) A health care professional authorized to prescribe an opioid antagonist may prescribe, dispense, or distribute, directly or by standing order, an opioid antagonist to a person at risk of experiencing an opioid-related overdose or a family member, friend, or other person in a position to assist a person at risk of experiencing an opioid-related overdose. Any such prescription shall be regarded as being issued for a legitimate medical purpose in the usual course of professional practice.
Copy linkA person or organization may, if acting pursuant to the provisions of subparagraph (a), store and possess an opioid antagonist, dispense or distribute an opioid antagonist, and administer an opioid antagonist to another person who the person believes is suffering an opioid-related overdose.
Copy linkNo health care professional who, acting in good faith and with reasonable care, prescribes, dispenses, or distributes an opioid antagonist directly or by standing order and no person who, acting in good faith and with reasonable care, stores, dispenses, or distributes an opioid antagonist or administers an opioid antagonist to another person who the person believes is suffering an opioid-related drug overdose shall be subject to any criminal or civil liability, or any professional disciplinary action, for any action authorized by this paragraph or any outcome resulting from an action authorized by this paragraph.
Copy link"Opioid antagonist" means any drug that binds to opioid receptors and blocks or disinhibits the effects of opioids acting on those receptors.
Copy link"Opioid-related drug overdose" means a condition including, but not limited to, extreme physical illness, decreased level of consciousness, respiratory depression, coma, or death resulting from the consumption or use of an opioid, or another substance with which an opioid was combined, or that a layperson would reasonably believe to be an opioid-related drug overdose that requires medical assistance. Source. 1969, 421:1. 2010, 173:1. 2011, 63:6. 2015, 65:1, eff. June 2, 2015.
Copy linkSource note
Source. 1969, 421:1. 2010, 173:1. 2011, 63:6. 2015, 65:1, eff. June 2, 2015.
Source history
- 1969, 421:1
- 2010, 173:1
- 2011, 63:6
- 2015, 65:1, eff. June 2, 2015
Related materials
Bill relationships
-
2026 HB1235
reference
es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s
-
2026 HB1235-FN
reference
es on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This section s
-
2026 HB1237
reference
owledging the receipt and understanding of the policy. XXII. Excluding the drugs described in 49 C.F.R. section 392.4 of the federal Motor Carrier regulations and outlined under RSA 318-B, the only drugs that may be transported are those legally prescribed by a licensed physician, in their original container, and in the possession of the person who is prescribed them. XXIII. A tow business whose driver
-
2026 HB1423
amend · effective 2027-01-01
ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de
-
2026 HB1423-FN
amend · effective 2027-01-01
ffect without the invalid provision or application, and to this end the provisions of this act are declared to be severable. 3 New Subdivision; Synthetic Kratom Policy. Amend RSA 318-B by inserting after section 50 the following new subdivision: Synthetic Kratom Policy 318-B:51 Definitions. In this subdivision, "synthetic kratom" or "semisynthetic kratom" means: I. An alkaloid or alkaloid de
-
2026 HB1796
reference · effective 2027-01-01
arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t
-
2026 HB1796-FN
reference · effective 2027-01-01
arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t
-
2026 HB186
reference
of Drugs. Any person who drives on any way a vehicle while knowingly having in his or her possession or in any part of the vehicle a controlled drug or controlled drug analog in violation of the provisions of RSA 318-B shall be guilty of a misdemeanor, and his or her license shall be revoked or his or her right to drive denied for a period of 60 days and at the discretion of the court for a period not to exceed 2 years. This
-
2026 HB186-FN-A
amend
. 5 Model Drug Dealer Liability Act; Definition of Illegal Drug. Amend RSA 318-C:4, I to read as follows: I. "Illegal drug" means any drug which is a schedule I-IV drug under RSA 318-B, the possession, use, manufacture, sale, or transportation of which is not otherwise authorized by law. 6 New Chapter; Regulation of Cannabis. Amend RSA by inserting after chapter 318-E the following new chapter: CH
-
2026 HB194
reference · effective 2027-01-01
als under pharmacist supervision. A licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performan
-
2026 HB194-FN
reference · effective 2027-01-01
licensee or registrant of the board of pharmacy shall independently determine whether: (a) The act is expressly prohibited by: (1) This chapter; (2) The controlled drug act, RSA 318-B; (3) The rules of the board of pharmacy; or (4) Any other applicable state or federal laws or regulations; (b) The act is consistent with the individual's education, training, and experience; and (c) Performance
-
2026 SB465
amend · effective 2027-01-01
s a schedule III controlled drug. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Controlled Drug Act; Xylazine. Amend RSA 318-B by inserting after section 1-c the following new section: 318-B:1-d Xylazine. I. Notwithstanding the provisions of RSA 318-B:1-a, relative to scheduling by rulemaking of the commissioner of the department of healt